July 11, 2017. By Gordon Gibb.
Philadelphia, PA: On the day that the Philadelphia Court of Common Pleas is holding a status update and discussion on the Risperdal lawsuit file, (July 11, 2017) it’s instructive to look rearwards a year and a week to July 1, 2016 when a $70 million verdict was delivered by a Pennsylvania state court jury favoring the plaintiff in a Risperdal gynecomastia lawsuit.Read [ One Year after Blockbuster Risperdal Gynecomastia Award, Lawsuits Now Top 20,000 ]
June 25, 2017. By Gordon Gibb.
Philadelphia, PA: The Risperdal lawsuit count now stands at a number above 18,000. To that end a staggering number of cases name pharmaceutical giants Johnson & Johnson (J&J) and subsidiary Janssen Pharmaceuticals as defendants. Most allege Risperdal gynecomastia, a Risperdal side effect characterized as the growth of male breast tissue. However one Risperdal lawsuit was recently filed in Missouri alleging that Risperdal had been prescribed to children as young as two years of age.Read [ Risperdal Lawsuit Hit 18,000 and Climbing, Status Update Due in July ]
June 14, 2017. By Jane Mundy.
Plattsmouth, NE: Most of us don’t think twice to talk with our doctor if we think there is an issue—a side effect—associated with a prescribed medication. But many people with mental illness don’t have the wherewithal to seek help. Such is the case with Jared, who was prescribed Risperdal for bipolar disorder and schizophrenia. He developed gynecomastia, or “man boobs” and was unable to talk about it with his doctors, most of whom were at hospitals for mentally ill patients.Read [ Seeking Help Difficult for Bipolar Man with Risperdal “Man Boobs” ]
May 23, 2017. By Jane Mundy.
Detroit, MI: Most jurors in Risperdal trials are likely sympathetic and at the same time shocked to discover how boys who developed female breasts have suffered. The public are likely reacting the same way after seeing a photo project online titled “Risperdal Boys”.Read [ Risperdal Victims Candid Photographs Speak Volumes ]
May 4, 2017. By Gordon Gibb.
Philadelphia, PA: A Risperdal lawsuit that was initially stopped following a health issue on the part of a jurist, restarted and then thrown out on the second try will be up for a third go if the plaintiff has his way.Read [ Risperdal Lawsuit Plaintiff Up for a Third Try ]
April 30, 2017. By Gordon Gibb.
Philadelphia, PA: A Risperdal lawsuit that had to be stopped and restarted after a juror suffered a health emergency, has been tossed by a Philadelphia judge after appearing to agree with defendant Janssen Pharmaceuticals that the plaintiff failed to provide sufficient evidence to fully support his claim of Risperdal gynecomastia, a condition characterized by the growth of male breast tissue. The judge, in issuing his order to dismiss the case, gave no further details.Read [ Yet Another Risperdal Lawsuit Tossed in Philadelphia ]
April 7, 2017. By Gordon Gibb.
Philadelphia, PA: The seventh Risperdal lawsuit in the mass tort in Philadelphia has heard opening arguments, with attorneys for the plaintiff suggesting that 8-year-old boys should not be growing male breasts. Legal counsel for the defense shot back that plaintiff Dean Hibbs, now 23, was obese to begin with and only took Risperdal for a period of seven months.Read [ Latest Risperdal Trial Restarted After Health Emergency Resulted in a Mistrial ]
March 20, 2017. By Gordon Gibb.
Philadelphia, PA: A Risperdal lawsuit that alleged the growth of male breast tissue (Risperdal gynecomastia) suffered by the plaintiff was stopped dead in its tracks before a trial reached the verdict stage after a Pennsylvania judge determined that Johnson & Johnson (J&J) and its Risperdal unit, Janssen Pharmaceuticals Inc. (Janssen) had not failed to adequately warn about gynecomastia risk as the plaintiff had asserted, thus pulling the rug out from under the lawsuit.Read [ Recent Risperdal Lawsuit Tossed, Plaintiffs Plan to Appeal ]
March 7, 2017. By Deb Hipp.
New Brunswick, NJ:There are now 18,500 Risperdal lawsuits pending against Johnson & Johnson (J & J) and its subsidiary Janssen Pharmaceuticals in the US and Canada, according to Johnson & Johnson's most recent annual report.Read [ Number of Pending Risperdal Lawsuits Grows to 18,500 Cases ]
February 21, 2017. By Gordon Gibb.
Philadelphia, PA: With Risperdal side effects lawsuits continuing to grow at a compelling rate within a mass tort in the Philadelphia Court of Common Pleas, the file is poised to move forward with a meeting planned for March 9 with regard to the centralized litigation (In Re: Risperdal Litigation, Case No. 100300296).Read [ Risperdal Case Load Shows No Sign of Slowing Down ]